. 2007 Feb 21;6:21. doi: 10.1186/1475-2875-6-21

Table 3.

Incremental cost-effectiveness of artemether-lumefantrine including second line treatment

	AL	SP
1. Total patients	55,509	55,509
2. First wave first-line, US$^a	407,436.06	343,600.71
3. Second wave first-line, US$^b	58,263.36	143,968.70
4. Second line treatment, US$^c	6,088.60	182,575.57
5. Incremental cost, US$	-176,486.97	-
6. ACER including second line treatment, US$	9.92	20.78
7. ICER including second line treatment, US$	-11.52	-

(a) All patients receive first wave first-line

(b) 14.7% of AL and 41.9% of SP recipients fail first-line and receive repeated dosage